Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Genocea Begins Dosing of Phase 2b GEN-003 for Genital Herpes Treatment

Source Link:: http://ir.genocea.com/releasedetail.cfm?ReleaseID=952378

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GNCA

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Genocea began dosing patients for its Phase 2b trial of GEN-003 for genital herpes treatment. This trial will study GEN-003's efficacy of viral shedding rate on 135 patients from 9 institutions. The 6 month trial is expected to end and release the data in mid-2016. Phase 2 data is expected to be released in Q1 of 2016 and showed promising results in a interim analysis in October '15.

http://ir.genocea.co...

Additional Relevant Details For our recently initiated Phase 2b efficacy trial, we anticipate reporting virologic efficacy data in the third quarter of 2016

http://ir.genocea.co...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jul 09, 2016

Occurred Source:

http://ir.genocea.com/releasedetail.cfm?ReleaseID=975006

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2b, Gen-003, Genital Herpes